Další formáty:
BibTeX
LaTeX
RIS
@article{1775028,
author = {Ludwig, H and Ponisch, W and Knop, S and Egle, A and Hinke, A and Schreder, M and Lechner, D and Hajek, R and Gunsilius, E and Petzer, A and Weisel, K and Niederwieser, D and Einsele, H and Willenbacher, W and Rumpold, H and Pour, Luděk and Jelinek, T and Krenosz, KJ and Meckl, A and Nolte, S and Melchardt, T and Greil, R and Zojer, N},
article_location = {LONDON},
article_number = {2},
doi = {http://dx.doi.org/10.1080/10428194.2019.1666381},
keywords = {Multiple myeloma; quality of life; ixazomib; thalidomide; relapsed; refractory disease},
language = {eng},
issn = {1042-8194},
journal = {LEUKEMIA & LYMPHOMA},
note = {Bez afiliace k MU.},
title = {Quality of life in patients with relapsed/refractory multiple myeloma during ixazomib-thalidomide-dexamethasone induction and ixazomib maintenance therapy and comparison to the general population},
volume = {61},
year = {2020}
}
TY - JOUR
ID - 1775028
AU - Ludwig, H - Ponisch, W - Knop, S - Egle, A - Hinke, A - Schreder, M - Lechner, D - Hajek, R - Gunsilius, E - Petzer, A - Weisel, K - Niederwieser, D - Einsele, H - Willenbacher, W - Rumpold, H - Pour, Luděk - Jelinek, T - Krenosz, KJ - Meckl, A - Nolte, S - Melchardt, T - Greil, R - Zojer, N
PY - 2020
TI - Quality of life in patients with relapsed/refractory multiple myeloma during ixazomib-thalidomide-dexamethasone induction and ixazomib maintenance therapy and comparison to the general population
JF - LEUKEMIA & LYMPHOMA
VL - 61
IS - 2
SP - 377-386
EP - 377-386
PB - INFORMA HEALTHCARE
SN - 10428194
N1 - Bez afiliace k MU.
KW - Multiple myeloma
KW - quality of life
KW - ixazomib
KW - thalidomide
KW - relapsed
KW - refractory disease
N2 - This trial evaluated quality of life (QoL) using the EORTC QLQ-C30 and the EORTC QLQ-MY20 instruments in 90 patients with relapsed/refractory multiple myeloma during induction and maintenance therapy with eight cycles of ixazomib-thalidomide-dexamethasone, followed by 12 months of ixazomib maintenance therapy. When patient's baseline QoL was compared with data of the general population, a significant impairment in health-related QoL, physical, role, and social functioning and several other dimensions, as well as more pain and fatigue, was noted. Induction therapy resulted in significant improvement of pain and worsening of neuropathy, with no significant variation of other parameters. During maintenance treatment, scores for most dimensions including health-related QoL, physical functioning and pain, improved, while for neuropathy no improvement was observed. Time to deterioration (>= 10 score points) of health-related QoL, physical functioning, pain, and neuropathy was distinctly shorter than time to progression. Health-related QoL and physical functioning at baseline correlated with overall survival.
ER -
LUDWIG, H, W PONISCH, S KNOP, A EGLE, A HINKE, M SCHREDER, D LECHNER, R HAJEK, E GUNSILIUS, A PETZER, K WEISEL, D NIEDERWIESER, H EINSELE, W WILLENBACHER, H RUMPOLD, Luděk POUR, T JELINEK, KJ KRENOSZ, A MECKL, S NOLTE, T MELCHARDT, R GREIL a N ZOJER. Quality of life in patients with relapsed/refractory multiple myeloma during ixazomib-thalidomide-dexamethasone induction and ixazomib maintenance therapy and comparison to the general population. \textit{LEUKEMIA \&{}amp; LYMPHOMA}. LONDON: INFORMA HEALTHCARE, 2020, roč.~61, č.~2, s.~377-386. ISSN~1042-8194. Dostupné z: https://dx.doi.org/10.1080/10428194.2019.1666381.
|
